Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04686175 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
A Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets, sponsored by Inozyme Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 7
- Study locations
NCT04686175 is a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets that has completed, run by Inozyme Pharma. The registered enrollment target is 9 participants, below the 81-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT04686175, a Phase 1 study of Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency and Autosomal Recessive Hypophosphatemic Rickets, has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for the treatment of ENPP1 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ENPP1 Deficiency.
Conditions Studied
Interventions
- DRUG INZ-701
Study Locations (7)
Other
- Necker University Hospital-Sick Children - Paris
- Parexel International GmbH - Berlin
- University of Hamburg (Universitatklinikum Hamburg-Eppendorf) - Hamburg
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Clinilabs Drug Development Corporation - Eatontown
Saskatchewan
- University of Saskatchewan - Saskatoon
London Bridge
- Richmond Pharmacology (RPL) - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-11-21 |
| Est. Completion | 2024-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04686175
The ClinicalTrials.gov registry entry for NCT04686175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 3 other Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials with a reported enrollment target (89% lower). The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency appearing as the primary indexed condition, and to 1 intervention - of which INZ-701 is the first listed.
NCT04686175 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Minnesota, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04686175 about?
NCT04686175 is a clinical study titled "Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for the treatment of ENPP1 Deficiency. The goal of the s...
What is the current status of trial NCT04686175?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-11-21. Estimated completion is 2024-12-13.
What conditions does trial NCT04686175 study?
This clinical trial studies the following conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy.
What interventions are being tested in trial NCT04686175?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT04686175?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04686175 being conducted?
This trial has 7 study locations across Minnesota, New Jersey, Saskatchewan, London Bridge. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
All registered trials for this condition
Autosomal Recessive Hypophosphatemic Rickets
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.